Voyager Therapeutics, Inc. (VYGR) Stock Forecast
VYGR analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 11 analysts
- Price target
- $14.89 average of analyst targets
- Upside to target
- +683.6% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.41
- 52-week range
- $1.90 – $5.07
VYGR analyst ratings
11 analystsNumber of analysts at each rating.
VYGR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
VYGR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.42 | −$0.80 | −$0.28 | −$0.47 | +11.1% | 10 |
| Current fiscal year (2026) | −$1.70 | −$2.62 | −$1.24 | −$2.04 | +16.4% | 10 |
| Next fiscal year (2027) | −$1.28 | −$1.86 | −$0.51 | −$1.70 | +25.0% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
VYGR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $6.3M | $31,000 | $15.0M | −52.5% | 11 |
| Current fiscal year (2026) | $20.3M | $11.8M | $49.3M | −49.8% | 11 |
| Next fiscal year (2027) | $46.6M | $10.0M | $141.5M | +129.8% | 11 |
VYGR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
VYGR revenue: reported and forecast
VYGR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.48 | −$0.42 | −$0.42 | −$0.42 | −$0.42 | −12.0% | 3 up · 0 down |
| Current fiscal year (2026) | −$1.66 | −$1.70 | −$1.70 | −$1.70 | −$1.70 | +2.9% | 3 up · 0 down |
| Next fiscal year (2027) | −$1.56 | −$1.28 | −$1.28 | −$1.28 | −$1.28 | −18.0% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
VYGR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; VYGR beat in 9 of 12.
What analysts expect from VYGR
11 analysts cover Voyager Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $14.89, 683.6% above the latest close of $1.90. Analysts expect earnings of −$1.70 per share for 2026, +16.4% from a year earlier. For 2027 the average estimate is −$1.28 per share on revenue of $46.6 million. Voyager Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: VYGR income statement, VYGR key metrics, VYGR chart. See the VYGR stock overview for the latest quote and news.
VYGR forecast FAQ
What is Voyager Therapeutics's price target?
The average analyst price target for Voyager Therapeutics is $14.89, 683.6% above the latest close of $1.90.
Is Voyager Therapeutics a buy, hold or sell?
Of 11 analysts covering Voyager Therapeutics, 11 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Voyager Therapeutics's EPS forecast?
Analysts forecast −$1.70 per share for 2026 (range −$2.62 to −$1.24); for 2027 the estimate is −$1.28.
What is Voyager Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $20.3 million, growth of −49.8%; for 2027 it is $46.6 million.
When does Voyager Therapeutics report earnings?
Voyager Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026 after the market closes; the EPS estimate is $-0.41.
Does Voyager Therapeutics usually beat earnings estimates?
Voyager Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.